ArticleNature reviews. Clinical oncology2023
Newly approved cancer drugs in China - innovation and clinical benefit.
Article in Nature reviews. Clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparison of treatment efficacy of targeted therapies approved in China for non-small cell lung cancer before and after the introduction of accelerated drug marketing registration procedures.International journal of clinical pharmacy · 2026Pooled it
- Article
- A cross-national review of novel oncology approvals in the United States and China (2020-2025).Health affairs scholar · 2026Article
- Clinical value and cost-effectiveness analysis of conditionally approved anticancer drugs in China from 2015 to 2023.Translational cancer research · 2026Article
- Association of haematological cancer drugs recommendation levels in Chinese Society of Clinical Oncology guideline with different approval approaches: a cross-sectional study.BMJ public health · 2026Article
- Regulatory approval, reimbursement and postmarketing evidence of class 1 novel drugs in China, 2018-2023: an observational study.BMJ public health · 2026Article
- Cancer Drugs Approved Based on Surrogate Endpoint: A Retrospective Observational Study in the United States and China.Cancer medicine · 2025Observational
- Impact of competition on reimbursement decisions for cancer drugs in China: an observational study.The Lancet regional health. Western Pacific · 2024Article
- Access to essential and innovative anti-cancer medicines: a longitudinal study in Nanjing, China.BMC health services research · 2024Article
- List prices and clinical value of anticancer drugs in China, Japan, and South Korea: a retrospective comparative study.The Lancet regional health. Western Pacific · 2024Article
- Article
- Use of suboptimal control arms in randomized clinical trials of investigational cancer drugs in China, 2016-2021: An observational study.PLoS medicine · 2023Observational
- National value-based pricing negotiation for oncology drugs - lessons from China.Nature reviews. Clinical oncology · 2023Article
- Bridging the new drug access gap between China and the United States and its related policies.Frontiers in pharmacology · 2023Article
- Review time of oncology drugs and its underlying factors: an exploration in China.Frontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
36646814What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.